Loading clinical trials...

Optical Coherence Tomography Angiography and in Fluorescein Angiography in Diabetic Retinopathy | Clinical Trials | Clareo Health

Back to clinical trial search

UNKNOWNNCT05190965

Optical Coherence Tomography Angiography and in Fluorescein Angiography in Diabetic Retinopathy

Diabetic retinopathy (DR) is the leading cause of decreased vision in working age people. Patients with DR can develop macular edema and proliferative retinopathy which are major causes of visual impa...

Lead sponsor: Assiut University•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Contacts

Esraa Resident Reda Mohamed

CONTACT

01092564344 esraareda54321@gmail.com

Wael Prof Mohamed Ahmed Soliman

CONTACT

Trial snapshot

StatusUNKNOWN

Phase—

Enrollment40

Start dateSep 2022

Last updatedJan 13, 2022

Condition

OctA .FFA Findings in DR

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 13, 2022Data synced to Clareo: May 3, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions